Kristin Brooks on Muck Rack

Kristin Brooks

Verified
As seen in: Contract Pharma, Medium, Inside Higher Ed, EIN News, EIN Presswire, Nutraceuticals World, Heights Observer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kristin

Contact Kristin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

When Did We Become These People?

|
By Kristin Brooks Verified
| Medium
Some things require a woman’s touch. That could mean gentle, caring, or loving, but it could also mean determined, decisive, or indisputable. Come with me along a journey to feel the depth of life, in full color, uncensored, unfiltered, raw, magnetic, and deliciously clever. When did we become these people, So jaded and unfeeling to the disconnect, In our attempts to create that which connects us Effortlessly, Endlessly, Easily.
Open in Who Shared Issue with article?

CRO Industry Outsourcing Trends Report

|
By Kristin Brooks Verified
| Contract Pharma Verified
Navigating the complexity of today’s drug development landscape grows more challenging every day with emerging and advanced biopharmaceuticals, vast amounts of data, new technologies, and evolving regulatory requirements. Pharma and biopharma companies increasingly engage CROs to help expedite development leveraging clinical trial management, data, therapeutic, and regulatory expertise.
Open in Who Shared Issue with article?

An Inflection Point in Obesity R&D

|
By Kristin Brooks Verified
| Contract Pharma Verified
The World Obesity Federation’s Global Obesity Observatory estimates that 1 billion adults will have obesity by 2030, and more than half of the world’s population1 will live with overweight or obesity levels by 2035. As such, there has been tremendous focus and growth in obesity drug development, with Wegovy (semaglutide) and Zepbound (tirzepatide) becoming household names in recent years.
Open in Who Shared Issue with article?
See all 114 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified